Jacobio Pharma chairman and CEO Dr Yinxiang Wang (right) and Jinxiang Du (left) at the agreement signing ceremony. Credit: JACOBIO PHARMACEUTICALS GROUP CO., LTD.

Jacobio Pharma has out-licensed the China rights of its assets, glecirasib and JAB-3312, to Shanghai Allist Pharmaceuticals.

Glecirasib is a Kirsten rat sarcoma glycine 12 to cysteine inhibitor. JAB-3312 is a Src homology-2 domain-containing protein tyrosine phosphatase 2 inhibitor.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The agreement includes mainland China, Hong Kong, Macau and Taiwan rights.

Jacobio is entitled to receive 200m yuan ($28m) in the near term, which includes 150m yuan in upfront payment and 50m yuan for research and development expenses and other payments

The agreement also includes milestone payments of 700m yuan contingent upon meeting specific development, regulatory and commercial goals.

See Also:

Jacobio is entitled to receive tiered royalty payments on net product sales from Allist. Royalty payments for JAB-3312 could reach 20%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Allist will handle the commercialisation of the assets in China and cover subsequent expenditures for their clinical development.

A new drug application for glecirasib monotherapy for second-line non-small cell lung cancer (NSCLC) with KRAS G12C mutation received priority review in May 2024 and breakthrough therapy designation in December 2022 in China.

In April 2024, data from a Phase II study of glecirasib showed a confirmed objective response rate of 47.9% in second-line NSCLC patients.

The disease control rate was 86.3%, with median progression-free survival of 8.2 months and median overall survival of 13.6 months.

The first subject was recently dosed in a Phase III clinical trial of the glecirasib and JAB-3312 combination versus standard care.

In addition to NSCLC, glecirasib is undergoing pivotal studies for second-line or above pancreatic cancer and in combination with cetuximab for colorectal cancer.

Jacobio Pharma chairman and CEO Dr Wang Yinxiang stated: “Allist has strong commercialisation capabilities in the field of lung cancer, and the first indication for glecirasib submitted the new drug application is lung cancer. We believe that with the deep fit of the advantages of both parties, this collaboration will demonstrate great clinical and commercial value.

“In addition to the co-operation with glecirasib, Allist also licensed-in the SHP2 inhibitor JAB-3312, the first SHP2 inhibitor entering a registrational trial globally. It is expected to become a first-line therapy in combo with glecirasib, which reflects Allist’s foresight into the future of pipelines.”